X0508 4 2021-02-23 0001439725 BIODESIX INC BDSX 0001828131 O'Kane Kieran 2970 WILDERNESS PLACE SUITE 100 BOULDER CO 80301 true Chief Commercial Officer false Stock Options (Right to buy) 20.67 2021-02-23 4 A 0 25599 0 A 2031-02-22 Common Stock 25599 25599 D Stock Options (Right to buy) 20.67 2021-02-23 4 A 0 31055 0 A 2031-02-22 Common Stock 31055 31055 D Stock Options (Right to buy) 20.67 2023-07-24 4 D 0 25599 D 2031-02-22 Common Stock 25599 0 D Stock Options (Right to buy) 20.67 2023-07-24 4 D 0 31055 D 2031-02-22 Common Stock 31055 0 D Stock Options (Right to buy) 1.2 2023-07-24 4 A 0 11564 A 2033-07-23 Common Stock 11564 11564 D This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021. This option was fully vested as of the grant date. On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023. The Reporting Person elected to participate in the Tender Offer and received 11,564 Replacement Options with an exercise price of $1.20 per share in exchange for 56,654 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled. This Replacement Option vests as follows: 8,864 shares of Common Stock underlying this Replacement Option vest on August 1, 2024, and the remaining 2,700 shares of Common Stock underlying this Replacement Option vest in 31 successive, equal monthly installments beginning on August 1, 2024. /s/ Robin Harper Cowie as Attorney-in-Fact for Kieran O'Kane 2023-07-26